Search results
Novartis to buy radiology drug specialist Mariana for $1 billion
Reuters via AOL· 4 hours agoNovartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront,...
Sen. Hassan slams GlaxoSmithKline over cost of asthma inhalers
New Hampshire Union Leader· 15 hours agoLess than two months after GlaxoSmithKline pledged...Sen. Maggie Hassan, D-N.H., is accusing the ...
California is joining with a New Jersey company to buy a generic opioid overdose reversal drug
KSBY San Luis Obispo· 3 days agoCalifornia is partnering with a New Jersey-based pharmaceutical company to purchase a generic...
FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How
Forbes· 2 days agoThe FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca,...
Charles Gore
Time Magazine· 3 hours agoThe organization Gore leads as executive director, the Medicines Patent Pool, offers a creative solution to the patent restrictions that can keep drugs...
California is joining with a New Jersey company to make a generic opioid overdose reversal drug
ABC 10 Sacramento· 3 days agoCalifornia will soon begin selling its own generic version of Narcan — the drug that can save...
Earnings call: Corcept Therapeutics raises 2024 revenue guidance By Investing.com
Investing.com· 6 hours agoThe company has also raised its revenue guidance for the full year to between $620 million and $650...
California is joining with a New Jersey company to make a generic opioid overdose reversal drug
NBC Bay Area· 3 days agoCalifornia will soon begin selling its own generic version of Narcan — the drug that can save...
These Are the Drugs America Is Running Short On
247wallst.com· 3 days agoDrug shortages in America are the result of supply line challenges, profit-based operations, and company closures.
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
Zacks· 11 hours agoThis quarterly report represents an earnings surprise of -21.33%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. , which belongs ...